Microgenics Corporation

Microgenics Corporation, operating through its Clinical Diagnostics Division and doing business as Microgenics Corp, manufactures immunoassay reagent test kits for clinical toxicology screening and substance detection, serving the Department of Defense and Veterans Affairs as a prime contractor on a full-and-open, non-set-aside basis. The Fremont, California–based subsidiary of Thermo Electron Corporation competes exclusively in the unrestricted market across 1,490 prime federal awards with no subcontract footprint, holding a $83.6 million combined potential value portfolio concentrated in specialized diagnostic reagents for controlled-substance screening across military and veteran healthcare systems.

Microgenics' core capability centers on designing and supplying FDA-approved diagnostic reagent kits compatible with clinical analyzers such as Beckman Coulter AU5800 series systems. Representative products include DRI (Diagnostic Reagent Kit) immunoassay test kits for opiates, benzodiazepines, amphetamines, methamphetamine, MDMA/MDA, hydrocodone, benzoylecgonine, and oxycodone detection; EMIT II PLUS and CEDIA reagents for amphetamine, methamphetamine, and benzodiazepine assays; and beta-glucuronidase and calibrator products. Recent delivery orders exemplify the scope: a $175.7 million benzodiazepine reagent kit order to Air Education and Training Command awarded December 16, 2025; a $163.9 million benzodiazepine order for Tripler Army Medical Center, Hawaii issued April 21, 2026 by Army Medical Command; a $156.2 million benzodiazepine order from Defense Health Agency in May 2025; and a $121.0 million benzodiazepine order for AETC issued June 26, 2025. Microgenics also manufactures calibrators and controls—a January 2024 sole-source $235.1 million purchase order for negative urine calibrator from Department of the Army underscores its position as the only available source for specialized calibrator products.

Customer concentration is acute and government-driven. The Navy Bureau of Medicine and Surgery dominates, accounting for 682 awards (approximately 46% of the portfolio) and $57.2 million (approximately 69% of total potential value). The top five customers—Navy BUMED, Army Medical Command, Air Education and Training Command, Defense Health Agency, and Veterans Integrated Service Network 23—represent 70% of awards and 91% of combined potential value. Activity has averaged 63 awards per year over the past five years, declining from 76 awards in 2023 to 32 in 2026 year-to-date through September. Only four awards face ultimate completion within the next twenty-four months, representing $432 thousand in recompete exposure—a favorable trajectory suggesting stable contract renewals and low near-term churn risk.

Microgenics operates under five primary indefinite-delivery contract vehicles established with the Navy Bureau of Medicine and Surgery and Veterans Integrated Service Network 23. The Navy's Indefinite Delivery Contract for DRI Opiate 500ML Reagent Test Kits (awarded June 1, 2023, $750.4 million ceiling through May 31, 2028) has generated 108 task orders. The Navy's MDMA/MDA Reagent Kits IDC (awarded March 15, 2024, $1.15 billion ceiling through March 14, 2029) has issued 84 task orders. The Navy's AMP and METH Reagent Kits IDC (awarded January 30, 2025, $775.4 million ceiling through January 29, 2030) has produced 77 task orders. A single-award IDC with Veterans Integrated Service Network 23 for toxicology reagents (awarded December 8, 2024, $852.1 million ceiling through September 30, 2029) supports ongoing VA procurement. Additionally, Microgenics holds a Federal Supply Schedule position (V797P5752X) with 189 task orders valued at $1.1 million combined. These vehicles anchor customer access and reduce recompete frequency; the oldest IDC expires in mid-2028, and the most recent are set through 2029–2030, providing contract stability through the next several fiscal years.

The vendor competes on cost and technical merit in a highly specialized market segment. All 1,490 awards carry full-and-open, non-set-aside designations, reflecting Microgenics' established proprietary position in immunoassay reagent manufacturing and its lack of small-business eligibility or strategic pursuit of set-aside categories. Work is performed primarily at Microgenics' primary facility in Fremont, California, with subordinate manufacturing and fulfillment locations at San Antonio, Texas; Pomona, California; and Waukegan, Illinois (leveraging parent-company infrastructure), and delivered to military medical treatment facilities and VA centers nationwide and in overseas locations. The company operates as a pure prime contractor—no subcontract activity appears in the award portfolio, indicating vertical integration of design, manufacturing, and logistics.

Microgenics' NAICS footprint is highly concentrated: 1,172 of 1,490 awards (79%) fall under NAICS 325413 (In-Vitro Diagnostic Substance Manufacturing); 136 awards (9%) under 325413-related analytical instrument manufacturing; the remainder scattered across medical equipment, supplies, and chemical categories. PSC coding similarly reflects specialization: 967 awards (65%) carry PSC 6550 (In Vitro Diagnostic Substances, Reagents, Test Kits and Sets); 185 awards (12%) PSC 6505 (Drugs and Biologicals); 154 awards (10%) PSC 6515 (Laboratory Equipment and Supplies). This concentration underscores a single-industry positioning around DoD and VA drug-testing infrastructure supporting the Department of Defense Drug Demand Reduction Program.

As a subsidiary of Thermo Electron Corporation (parent UEI GMXUXVDSNL89), Microgenics leverages parent-company financial capacity, manufacturing scale, and distribution infrastructure while maintaining independent federal contracting authority. Thermo Electron itself holds federal contract vehicles and has received over $9.5 million in blanket purchase agreements and other federal awards; this parent relationship provides working capital flexibility and risk mitigation. The Clinical Diagnostics Division structure allows Microgenics to maintain focused operational control while benefiting from Thermo Electron's broader scientific and industrial capabilities.

No recompete cliff or significant pipeline disruption is evident in the near term. The four awards completing in the next twenty-four months represent routine fulfillment and option-year exercises rather than large vehicle recompetes. Microgenics' established position as the primary federally designated supplier for immunoassay reagents across the military healthcare system, combined with long-dated contract vehicles and high switching costs (analyzer compatibility, regulatory clearance, clinical validation), creates a defensible market position. The vendor does not compete in other federal markets, operate as a subcontractor, or pursue growth outside the DoD/VA toxicology testing space, making competitive entry or displacement difficult for new market entrants without equivalent manufacturing capability and regulatory approvals.